Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Key facts
- Where
- Bengaluru, Chennai, Gurugramam, Jaipur, Kochi, Mumbai, New Delhi, and Secunderabad, IndiaSee the 12 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT04613921, who can take part
Where in India
- Aster CMI HospitalBengaluru, IndiaContact: Sonal Asthana, MDNot yet recruiting
- Dr.Rela Institute & Medical CentreChennai, IndiaContact: Mohamed Rela, PITaking people
- Fortis Hospital Noida, FEHI, FMRIGurugramam, IndiaContact: Vivek Vij, PINot yet recruiting
- Medanta MedicityGurugramam, IndiaContact: Arvinder Singh SoinNot yet recruiting
- Mahatma Gandhi University of Medical Sciences and TechnologyJaipur, IndiaContact: Vivek Saraswat, ProfNot yet recruiting
- Amrita institute of Medical SciencesKochi, IndiaContact: S SudhindranTaking people
- Global Hospital - Super Speciality & Transplant CentreMumbai, IndiaContact: Samir Shah, PiNot yet recruiting
- Kasturba HospitalMumbai, IndiaContact: Shiran Shetty, MDNot yet recruiting
- Seth GSMC & KEM HospitalMumbai, IndiaContact: Akash ShuklaNot yet recruiting
- Indraprastha Apollo HospitalsNew Delhi, IndiaContact: Ashish Malik, MDNot yet recruiting
- Max Saket HospitalNew Delhi, IndiaContact: Anna BoschNo longer taking part
- Yashoda HospitalsSecunderabad, IndiaContact: Darmesh Kapoor, PINot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- European Foundation for Study of Chronic Liver Failure
- Trial code
- NCT04613921
- Record updated
- 20 October 2025
- Original description
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.Read full original descriptionShow less
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.
Inclusion: 1. Male or female subject ≥18 years of age; Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology); Subjects who have been hospitalized for acute decompensation of liver cirrhosis and referred to the transplant team:; Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list; Group 2: patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD>20) at the time of listing; Group 3: patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation; Patients (or trusted person, family member or close relation if the patient is unable to express consent) who have been informed and signed their informed consent Inclusion criteria.
Exclusion: -.